Holen Sie sich die Stockscreener-App
6.76
1.05%
0.07
Handel nachbörslich:
6.75
-0.010
-0.15%
Schlusskurs vom Vortag:
$6.69
Offen:
$6.95
24-Stunden-Volumen:
433.90K
Relative Volume:
23.23
Marktkapitalisierung:
$337.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+8.68%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.75
$7.6999
1-Wochen-Bereich:
$6.04
$7.6999
52-Wochen-Spanne:
$5.60
$7.6999
Anbio Biotechnology Stock (NNNN) Company Profile
Vergleichen Sie NNNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
6.76 | 337.96M | 0 | 0 | 0 | 0.00 |
|
ISRG
Intuitive Surgical Inc
|
566.98 | 205.74B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.45 | 65.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
94.14 | 46.26B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
233.10 | 34.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
91.65 | 18.19B | 3.90B | 392.30M | 288.10M | 1.95 |
Anbio Biotechnology Aktie (NNNN) Neueste Nachrichten
Kestra Medical ups IPO target to $150M - BioWorld Online
Unlocking Anbio's IPO: A Pivotal Shift in Global Diagnostics! - Mi Valle
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
IPO NewsUS IPO Weekly Recap: IPO calendar slows down with small listings - Renaissance Capital
Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps - Yahoo Finance
Anbio Biotechnology prices $8M IPO at $5 per share - MSN
Anbio Biotechnology’s IPO opens up 5% - Investing.com
Anbio Biotechnology’s IPO Set to Revolutionize Global Diagnostics - Mi Valle
NNNNAnbio Biotechnology Latest Stock News & Market Updates - StockTitan
Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East - PR Newswire
Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency - PR Newswire
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha
Anbio Biotechnology Unveils Comprehensive In-Vitro-Diagnostics Solutions at ADLM 2024 - PR Newswire
Anbio Biotechnology to Showcase at ADLM 2024 with Evolved In Vitro Diagnostic Solutions - PR Newswire
Anbio advances POC testing with new FIA analyzer - SelectScience
Anbio Biotechnology to Showcase ABO & Rhd Blood Grouping Kit at Medlab Middle East 2024 - PR Newswire
Anbio Biotechnology to Present at Medlab Middle East on February 5th, 2024. - PR Newswire
Anbio Biotechnology made a successful first presence at AACC Middle East 2023 - BioSpace
Handheld Analyzer Uses LAMP Diagnostic Technique for Rapid, Point-of-Care Testing - HospiMedica
Anbio Biotechnology Highlights the Future of Diagnostic Solutions at AACC 2023 - PR Newswire
Anbio launches fluorescent immunoassay analyzer for rapid, point-of-care testing - BioWorld Online
Introducing the Anbio LAMP Solution: A Small, Yet Powerful Handheld Analyzer for Rapid, Point-of-Care Testing - PR Newswire
Anbio introduces fluorescent Immunoassay solution for patient care - Medical Device Network
Introducing the Anbio AF-100S: A Small, Yet Powerful Handheld Analyzer for Rapid, Point-of-Care Testing - PR Newswire
Introducing the Anbio ADL i1910: An Elegant CLIA Analyzer for Comprehensive Clinical Testing - PR Newswire
Anbio Biotechnology to Participate in the 2023 AACC Meeting - PR Newswire
AnHeart Therapeutics Raises $61 Million in Oversubscribed Series B Financing to Advance Precision Oncology Pipeline - Business Wire
Finanzdaten der Anbio Biotechnology-Aktie (NNNN)
Es liegen keine Finanzdaten für Anbio Biotechnology (NNNN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.97%
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):